Raymond James Maintains Outperform on Disc Medicine, Raises Price Target to $43
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Danielle Brill maintains an Outperform rating on Disc Medicine (NASDAQ:IRON) and raises the price target from $40 to $43.
May 10, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Raymond James has maintained its Outperform rating on Disc Medicine and increased the price target from $40 to $43, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst firm like Raymond James typically signals a strong conviction in the company's future performance. This endorsement can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100